Systemic mastocytosis (SM) is typically associated with CD25-positive mast cells (MCs) in the bone marrow (BM). The expression of CD25 in cutaneous MCs has shown to predict SM in adults. Recently, CD30 has emerged as a novel phenotypical marker of neoplastic MCs. The aim of this study was to investigate the patterns of expression of CD25 and CD30 on skin MCs in children with mastocytosis in the skin (MIS).
Introduction
Mastocytosis consists of a heterogeneous group of disorders characterized by the accumulation of mast cells (MCs) into different organs or tissues. According to the World Health Organization (WHO), mastocytosis can be divided into two main categories depending on the specific organs or tissues involved (Horny et al., 2008) : 1) cutaneous mastocytosis (CM), in which the accumulation of MCs is restricted to the skin, and 2) systemic mastocytosis (SM), when organs other than the skin, usually the bone marrow (BM), are affected with or without cutaneous involvement. CM is diagnosed by the demonstration of an abnormal proliferation of cutaneous MCs in a skin biopsy in the absence of criteria for SM; in turn, the diagnosis of SM is based, not only on histological considerations, but also on cytomorphological, phenotypical and molecular characteristics of MCs from BM samples (or from other extracutaneous organs) as well as on the levels of serum tryptase (sT) (Horny et al., 2008; Valent et al., 2007) . As a consequence, BM examination becomes necessary for the distinction between CM and SM according to the WHO classification. However, because pediatric mastocytosis frequently resolves by puberty, BM is not routinely investigated in children unless additional signs of systemic involvement are present and, therefore, the current WHO classification cannot be applied to the vast majority of pediatric cases. For this reason, the term mastocytosis in the skin (MIS) has emerged in recent years to provide a prediagnostic checkpoint for those patients with biopsy-proven mastocytosis involving the skin in whom BM study, that would definitively discriminate between CM and SM, is not performed (Valent et al., 2007) .
Currently it is well known that SM is a clonal disease that results from the existence of gain-offunction mutations of the proto-oncogen c-kit, mostly in exon 17 (i.e. D816V) that determine a constitutive, ligand-independent activation of the KIT receptor on MC surface which leads to their abnormal proliferation (Longley et al., 1996; Nagata et al., 1995) . Accordingly, D816V KIT mutation can be detected in the great majority (>90%) of SM patients and also in a proportion of patients with CM, provided that highly sensitive diagnostic methods are applied (Garcia-Montero et al., 2006; Bodemer et al., 2010; Kristensen et al., 2011) . Similarly, it is also well established that BM MCs aberrantly express CD25 in most SM cases (Orfao et al., 1996; Escribano et al., 1998a; Teodosio et al., 2010; Sánchez-Muñoz et al., 2011; Morgado et al., 2012) , this finding being widely considered as a surrogate marker for MC clonality. In recent years, CD30 has emerged as a new promising marker in the diagnostic work-up of mastocytosis which has been proven to be expressed by BM MCs in around 80% of SM (Morgado et al., 2013) .
In contrast to the increasing knowledge about the patterns of expression of the different phenotypical markers on neoplastic BM MCs, only limited data is currently available about the immunophenotypic profile of MCs from extramedullary organs in patients with mastocytosis. Furthermore, the few studies on this topic published so far involve small series of patients, mostly adults, in which the expression of either CD25 or CD30, but not both markers together, was investigated. Here we analyzed the patterns of expression of CD25 and CD30 on skin MCs in a group of 60 children with MIS and discussed their potential role for predicting systemic involvement.
Materials and methods

Patients
A total of 60 children -33 boys (55%) and 27 girls (45%)-diagnosed with MIS who were referred to the Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and for whom their parents gave an informed consent to participate were included in the study. Diagnosis of MIS was made on the basis of histological findings in skin biopsies according to the current accepted criteria (Valent et al., 2007) . Skin biopsies were either performed at the CLMast (n=25) or supplied as parafin-embedded specimens by the reference center from where the patients were referred (n=35). Age at disease onset and at diagnosis were defined as the age of the patient at which skin lesions were first noticed by their parents and the age at which the skin biopsy was performed, respectively. The specific subtype of MIS was determined in every case after a careful examination of the skin and classified according to the WHO classification further modified by Hartmann and Heinz (Hartmann & Henz, 2002) . Extensive skin disease was defined as MIS involving >90% of the body surface area (BSA) calculated as described elsewhere (Brockow, Akin, Huber, & Metcalfe, 2003) . In addition, sT levels (CAP; Phadia Diagnostics, Uppsala, Sweden) were measured at the time of skin biopsy in 58/60 patients.
Immunohistochemical studies
Immunohistochemical studies were performed on paraffin-embedded tissue sections which were subsequently dewaxed, rehydrated and subjected to antigen retrieval using Envision FLEX target retrieval solution, at high pH and heated at 95ºC. The slides were cooled and treated using Envision FLEX/HRP Technique (Dako, Glostrup, Denmark), counterstained with hematoxylin and mounted. The primary antibodies used were c-kit (rabbit policlonal, Dako), tryptase (clone AA1, Dako), CD25 (clone 4C9, Rocklin, CA, Cell Marque) and CD30 (clone Ber-H2, Dako). For both CD25 and CD30, staining intensity and proportion of immunoreactive cells were determined according to a scoring model based on the quickscore (Q-score) used for the assessement of the hormone receptor status in breast cancer (Barnes, Dublin, Fisher, Levison, & Millis, 1993; Detre, Saclani Jotti, & Dowsett, 1995) . Intensity of expression of CD25 and CD30 was scored as 0 (no staining), 1 (weak staining only visible at high magnification), 2 (moderate staining readily visible at low magnification), and 3 (strong staining strikingly positive at low magnification) (Figure 1 ). In cases with an intensity score <2, color-inverted images were used to improve the distinction between scores 0 and 1 (Figure 1 ). Extent of staining was graded as 0 (less than 5% of immunoreactive MCs), 1 (5-33% of immunoreactive MCs), 2 (34-66% of immunoreactive MCs) and 3 (≥67% of immunoreactive MCs). The overall immunoreactivity Q-scores for CD25 (CD25 Q-score) and for CD30 (CD30 Q-score) were calculated in every case by multiplication of the scores for intensity and extent obtained with each marker, their values ranging from 0 to 9. In addition, histological characteristics of skin MC infiltration such as density, distribution pattern and the predominant dermal layer involved were also recorded. All histological examinations were evaluated by three independent experts (LE, MM and IA-T).
Statistical analysis
For all continuous variables median and range were calculated while for categorical variables frequencies were reported. Differences between groups were determined using the Mann-Whitney U test (for continuos variables), the Jonckheere-Terpstra trend test (for ordinal variables) and the Pearson χ 2 and Fisher exact tests (for categorical variables). Multivariate ordinal logistic regression analysis was performed to determine which factors were independently associated with the increase or decrease of Q-score values when multiple factors showed statistically significant differences individually in the Jonckheere-Terpstra trend test. P-values ≤0.05 were considered to be associated with statistical significance. All statistical analyses were performed with the SPSS 20.0 statistical software package (SPSS; Chicago, IL, USA). 
Results
Clinical and laboratory findings
In all cases skin lesions emerged within the first 4 years of life, mostly (87%) within the first year, with a median (range) age at disease onset of 2 months (from birth to 48 months) (Table 1) . Noteworthy, skin lesions were already present at birth in a total of 23 patients (38%). Median (range) age at diagnosis was of 24 months (1 month-13 years) and median (range) time from disease onset to diagnosis was of 20 months (<1 month-13 years) (Table 1) .
Overall, MPCM was the most frequent subtype of MIS followed by NM and DCM (68%, 25% and 7% of cases, respectively) ( Table 1) and there was no correlation between the specific subtypes of MIS and gender or age at disease onset. Median sT levels at diagnosis was of 5.3 μg/L (range: 1 to 91.5 μg/L) and they were increased over the upper normal limit (>11.5 μg/L) in a total of 10 patients (17%) ( Table 1) . As expected, patients with extensive skin disease had significantly (p<.001) higher median sT levels vs. those without (14.7 vs. 4.6 μg/L; range, 5-91.5 vs. 1-19.4 μg/L, respectively). Accordingly, sT >20 μg/L was found in all the 4 cases with DCM and also in one patient with extensive NM involving >90% of the BSA. 
Histologic features
After careful examination of skin biopsies, three different histologic patterns of skin MC infiltration were identified (Table 2 ). In 38/60 cases (63%) MC infiltrates showed a perivascular distribution mainly located within the papillary dermis which was generally accompanied to a greater or lesser extent by an interstitial component; this pattern was found in all clinical forms of MIS, particularly in DCM and MPCM cases (75% and 73% of cases, respectively). The second histologic pattern in frequency (32% of cases) consisted on a dense sheet-like infiltration of MCs principally involving the whole papillary dermis and eventually extending deep into the reticular dermis which was also observed in all forms of MIS but mainly in NM (67% of cases). Finally, a nodular pattern consisting of large and well delimited nests of MCs usually within the reticular dermis was seen in only 3 patients (5%), all these cases clinically corresponding to MPCM.
By immunohistochemistry, CD25 was expressed on cutaneous MCs in 17/60 cases (28%) and CD30 in 49/60 cases (82%) ( Table 2) . Whereas no differences were observed regarding the overall frequency of CD30-positive cases among the different subtypes of MIS, CD25 was more frequently detected in NM compared to the other clinical variants (53% vs. 20%, p=0.01) ( Table 2) . ). Intensity of CD25 expression among CD25-positive cases ranged from weak (n=5, 29%) to moderate (n=12, 71%), with no cases showing a strong expression of this marker. In turn, intensity of CD30 expression among CD30-positive cases was weak in 13 patients (27%), moderate in 31 patients (63%) and strong in 5 patients (10%). The distribution of CD25 Q-score and CD30 Q-score values in the whole group of patients is depicted in Table 3 . There was no correlation between CD25 Q-score and any of the variables studied including gender, age at onset, extent of MIS, histological pattern, sT levels and the time from disease onset to diagnosis. In contrast, there was a positive correlation between CD30 Q-score and both the extent of MIS (p=0.024) and sT levels (p=0.019), and a negative correlation between CD30 Q-score and the time elapsed from disease onset to diagnosis (p=0.003). Multivariate ordinal logistic regression analysis identified the time to diagnosis as the only factor related to CD30 Q-score values, with a statistically significant negative correlation (OR=0.81 per year, 95%CI 0.71-0.94; p=0.004) (Table 4 and Figure 2) . Accordingly, all the 5 cases with a CD30 Q-score of 9 corresponded to biopsies performed within the first 4 months of disease whereas 9 out of the 11 cases with a CD30 Q-score of 0 (82%) were detected in samples collected beyond 3 years of disease onset. 
Discussion
The skin is one of the most frequently involved tissues in mastocytosis, particularly in pediatric patients. At present, it is widely accepted that BM studies for further investigation of SM in children with MIS should be resticted to the few patients who present with signs of advanced disease or to those who show persistently high sT levels, usually over 100 μg/L. By contrast, children with MIS and sT levels <20 μg/L are generally assumed to have CM with no further studies being required unless skin lesions persist after puberty (Valent et al., 2007 (Valent et al., , 2014 .
The definitive diagnosis of cutaneous involvement by mastocytosis has classically relied on the demonstration of a monomorphic MC infiltrate within lesional skin. Currently, there is robust evidence supporting that KIT mutations are closely associated with neoplastic MCs and that they can be detected not only in BM but also in skin biopsies from the vast majority of adults with SM who have cutaneous involvement, provided that highly sensitive methods are applied (Kristensen et al., 2013) . In children, a study by Sotlar et al. in 2003 found KIT mutations at codon 816 in lesional skin in 17/35 cases (41%) (Sotlar et al., 2003) , and a similar frequency (42%) has been more recently reported by Bodemer et al. in a study involving 50 children (Bodemer et al., 2010) . In agreement with these observations, the detection of KIT mutations at codon 816 in affected skin has been incorporated into the most current consensus diagnostic algorithm for MIS (Valent et al., 2007) . It should be highlighted that in the study by Bodemer et al., additional KIT mutations involving codons other than 816 were detected by direct sequencing techniques with a similar frequency (44%) to that found for mutations involving codon 816, resulting in an overall rate of KIT mutations of 86% (Bodemer et al., 2010) . Interestingly, KIT mutations at codon 816 including the typical D816V KIT mutation have been reported in the skin of children who ended up experiencing spontaneous resolution of their skin lesions (Sotlar et al., 2003) . Altogether, these observations indicate that pediatric MIS is a clonal disorder in nature and support that the identification of KIT mutations in skin biopsies does not necessarily imply by itself an increased risk for the persistence of the disease in adult age.
An alternative approach for establishing the clonal nature of MIS is the demonstration by immunohistochemistry of the aberrant expression of certain antigens on skin MCs which are virtually never expressed by normal or reactive MCs. Among these markers, CD25 has widely proven to be a reliable marker of neoplastic MCs when detected in BM MCs (Orfao et al., 1996; Escribano et al., 1998a Escribano et al., , 1998b Teodosio et al., 2010; Sánchez-Muñoz et al., 2011; Morgado et al., 2012) . Moreover, immunoreactivity for CD25 has been also demonstrated in extramedullary organs such as the gastrointestinal tract and the skin in adult patients with SM (Hahn and Hornick, 2007; Hollmann et al., 2008) . More recently, CD30 has emerged as a novel immunophenotypical marker with potential utility in the diagnostic work-up of SM. Although early reports of a few cases suggested an association between CD30 expression on BM MCs assessed by immunohistochemistry and advanced forms of mastocytosis Valent et al., 2011) , a recent study using flow cytometry in a larger series of patients has shown that CD30 is aberrantly expressed on BM MCs in 100% of aggressive SM but also in 80% of indolent SM, whereas the only 2 cases of MC leukemia included in the study were CD30 negative, challenging the hypothesis of the potential prognostic value of this marker in mastocytosis (Morgado et al., 2013) . In the skin, the expression of CD30 in patients with mastocytosis has not been studied in detail so far. To the best of our knowledge, there is only one study (published as an abstract) in which CD30 expression in skin biopsies from patients with CM has been evaluated, showing positive immunostaining in 50% of cases (Arredondo et al., 2011) ; however, this study only included 12 patients and did not provide further information on clinical or biological features that could contribute to establish the true role of CD30 expression on skin MCs.
In the present study we investigated for the first time the patterns of expression of both CD25 and CD30 on skin MCs in children with MIS and their potential role in predicting SM. One of the major limitations of immunohistochemical methods, particularly when the antigens investigated are expressed by different proportions of cells and/or at different levels of intensity, is the lack of standardized grading criteria. In our study, the immunohistochemical assessment of CD25 and CD30 was based on a scoring method widely used for solid tumors (Q-score) (Barnes, Dublin, Fisher, Levison, & Millis, 1993; Detre, Saclani Jotti, & Dowsett, 1995) , by which both the intensity of expression and the proportion of expressing cells are considered together. Overall, our results show that at least one of these markers was expressed by >5% of skin MCs in 86% of cases. Of note, whereas CD30 expression was detected in the great majority of patients, CD25 was restricted to a smaller, although significant, proportion of cases. Interestingly, the overall frequency of the CD25 and/or CD30 expression in our series perfectly fits with that of KIT mutations in skin biopsies from children with CM previoulsy reported (Bodemer et al., 2010) , which could support the notion that both immunophenotypical markers might be considered as surrogate markers for MC clonality when detected in skin MCs. However, the reliability of this hypothesis and whether every immunophenotypical pattern is associated with specific KIT mutations or with mutations involving specific domains of the KIT receptor deserve further investigations.
In our study, 28% of patients showed an aberrant expression of CD25 on their skin MCs, this finding being particularly frequent among children with NM. Our data contrast with those from previous studies which reported the systematic absence of CD25 staining on skin MCs in children with CM (Hollmann et al., 2008; Sundram and Natkunam, 2007) . Such discrepancy could be due to a larger sample size in our study, the absence of NM forms in other studies or differences in immunohistochemical methodologies. By contrast, a recent study in adults reported CD25 expression on skin MCs in 10/10 patients with SM and only in 5/20 patients with limited cutaneous disease, supporting that CD25 expression on cutaneous MCs could be highly predictive of SM (Hollmann et al., 2008) . Although the lack of BM analyses and follow-up data in our study makes it impossible to draw definitive conclusions about the true significance of the detection of CD25 expression on skin MCs at pediatric ages, if data from studies in adults are extrapolated to pediatric patients, then it could be speculated that children who show CD25-positive cutaneous MCs might be at increased risk for an underlying SM and, presumably, for the persistence of mastocytosis into the adulthood.
Our findings also provide new evidence that CD30 can be detected in the great majority of pediatric cases with MIS, and confirm and extend previous observations that CD30 expression on MCs is a diagnostic rather than prognostic marker of mastocytosis. Furthermore, the high percentage of patients with CD30 expression found in our series together with the well-known tendency in most children towards spontaneous regression with age suggest that the demonstration of CD30-positive cutaneous MCs in itself is not a reliable predictive marker for BM involvement by mastocytosis in pediatric patients. Previous studies in SM have shown that CD30 expression on BM MCs appears to be higher in patients with greater MC burden; however, in our series of pediatric MIS we found that the intensity of CD30 expression is not associated with skin MC density but, interestingly, it seems to inversely correlate with the time elapsed between the emergence of skin lesions and biopsy, suggesting that CD30 expression could gradually decrease throughout the course of the disease in most children. Whether these preliminary findings may translate into a potential association between the detection of CD30 expression on skin MCs at late childhood ages and an increased risk of an underlying SM remains unknown and deserves further studies.
In summary, our results provide the first evidence that an aberrant MC immunophenotype can be detected in skin biopsies in the majority of children with MIS and support the hypothesis that the detection of CD25 expression on cutaneous MCs might help to identify those patients at risk of having an underlying SM. Further studies with long-term follow up are warranted in order to determine the true role of the different immunophenotypical patterns of expression of CD25 and CD30 in the skin of pediatric MIS.
